Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Opinion CV Team Dispatch

July 2025 Dispatch for the CV Team

L.A. McKeown

July 24, 2025

News Daily News

Physical Activity Ebbs, Flows Over a Lifetime but Rarely Rebounds After CVD

Caitlin E. Cox

July 23, 2025

News Opinion Fellow Talk

The Hidden Demands of Cardiology Training

Tushar Mishra, MD

July 09, 2025

News Daily News

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Caitlin E. Cox

June 25, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

News Daily News

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

L.A. McKeown

April 14, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

News Daily News

Having Twins Ups the Risk of CVD Over the Next Year

Caitlin E. Cox

February 06, 2025

News Daily News

Misleading Statements Common in Online Ads for Compounded GLP-1s

L.A. McKeown

January 20, 2025

News Daily News

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

L.A. McKeown

January 10, 2025

Advertisement

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

July 2025 Dispatch for the CV Team

Physical Activity Ebbs, Flows Over a Lifetime but Rarely Rebounds After CVD

The Hidden Demands of Cardiology Training

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Having Twins Ups the Risk of CVD Over the Next Year

Misleading Statements Common in Online Ads for Compounded GLP-1s

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content